Floatz logo

Belantamab Mafodotin

Plasma Cell Neoplasm

Hellenic Society of Hematologyantibody_drug_conjugatePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Plasma Cell Neoplasm cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BBB
LENALIDOMIDE
Hellenic Society of Hematology
Phase 3BBB
Cyclophosphamide
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Fludarabine
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
FILGRASTIM
Hellenic Society of Hematology
Phase 3BB

View all 49 →

Same molecule, other indications

Belantamab Mafodotin is also rated in:

plasma cell myelomaActive
B
Indicative · Phase 3
58 / 100
View asset →
hematologic disorderActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
monoclonal gammopathyActive
CC
Indicative · Phase 1/2
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →